Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes

Telomir Pharmaceuticals, Inc.

Telomir-1 inhibited JMJD3, FBXL10, and FBXL11 histone demethylase enzymes in a Eurofins Discovery study.
Overactivation of these enzymes silences tumor suppressors and activates pro-inflammatory and metabolic genes.
Telomir-1 may restore normal gene expression, supporting development in cancer, autoimmune, neurodegeneration, and metabolic disorders.
Data builds on prior results showing Telomir-1 reversed epigenetic silencing of STAT1 and TMS1 in PC3 prostate cancer xenograft models.
Company is preparing to advance Telomir-1 into IND-enabling studies.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.